Study of Prevalence of Eating Disorder in Liver Transplant Patients

NCT06093919 | Completed

• 1 other identifier: F20230719110020
• Study Type: observational
• Target: 118
• Locations: 1 country
• Sites: 2

Brief Summary

The main goal of this observational study is to measure the prevalence of binge eating disorder in liver transplant patients by evaluating the responses to the Bulimia Test. Secondary objectives of the study are to:

• Determine the prevalence of binge eating disorders in liver transplant patients following alcoholic cirrhosis, evaluated by the Bulimia Test;
• Study the association between the presence of eating disorder behaviours and liver damage : hepatic steatosis and fibrosis determined by Fibroscan (Transient elastography and controlled attenuation parameter)
• Study the association between presence of eating disorder behaviours and alcohol use disorder, measured by Alcohol Use Disorders Identification Test-Consumption

Conditions

Eating Disorders; Eating Disorder Binge; Liver Transplant; Complications; Alcohol Use Disorder; Cirrhosis Alcoholic

Outcome Measures

Primary Outcomes (1)

• Prevalence of binge eating disorder in liver transplant patients

  The prevalence is defined as the percentage of liver transplant patients with a score higher than 88 on the Bulimia Test-Revised. The Bulimia Test-Revised is a validated test. It is a 36 item self-report questionnaire to assess the presence of bulimic symptoms. Scores range from 29-140 with those greater than 104 being indicative of bulimia nervosa.

  1 year

Secondary Outcomes (3)

• Prevalence for binge eating disorder in liver transplant patients following alcoholic cirrhosis

  1 year

• Correlation between the BulimiaTest-Revised score and liver damage determined by the Fibroscan

  1 year

• Correlation between the Bulimia-Test score and the Alcohol Use Disorders Identification Test-Consumption score

  1 year

Study Arms (1)

Liver transplant patients

This cohort will consist of all liver transplant patients followed between 01/01/2023 and 06/30/2024

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of all liver transplant patients at the University Hospital of Poitiers followed between 01/01/2023 and 06/30/2024

You may qualify if:

• over 18 years old
• had a liver transplant and followed at University Hospital of Poitiers
• responded to the Bulimia Test-Revised and to the Alcohol Use Disorders Identification Test-Consumption
• had a Fibroscan within the year

You may not qualify if:

• Patient without Fibroscan and not responded to both scale : Bulimia Test-Revised and Alcohol Use Disorders Identification Test-Consumption

Sponsors & Collaborators

• Centre Hospitalier Henri Laborit: lead

Study Sites (2)

Centre Hospitalier Henri Laborit

Poitiers, France

Location

University Hospital of Poitiers (CHU de Poitiers)

Poitiers, France

Location

MeSH Terms

Conditions

Feeding and Eating Disorders; Binge-Eating Disorder; Alcoholism; Liver Cirrhosis, Alcoholic

Condition Hierarchy (Ancestors)

Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Mental Disorders; Alcohol-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Liver Cirrhosis; Liver Diseases; Digestive System Diseases; Liver Diseases, Alcoholic; Fibrosis; Pathologic Processes; Alcohol-Induced Disorders

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 17, 2023
• First Posted: October 23, 2023
• Study Start: February 12, 2024
• Primary Completion: June 30, 2024
• Study Completion: August 14, 2024
• Last Updated: August 20, 2024

Record last verified: 2024-08

Locations

FR (2)